Heron Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Heron Therapeutics, Inc. (HRTX) on April 6, 2026, covering events that occurred on April 3, 2026. The filing details amendments to executive employment and retention agreements for the Company's CEO and three other senior executives.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on executive compensation terms and contractual amendments.
Material Changes and Executive Compensation
The Company entered into significant amendments to executive agreements on April 3, 2026:
- CEO Agreement (Craig Collard): An amended and restated employment agreement was executed.
- Standard Termination: Provides 100% of base salary plus 100% of target/average bonus, 12 months of equity vesting acceleration, and 18 months of COBRA coverage.
- Change in Control (CIC) Termination: Provides 200% of base salary plus 200% of target/average bonus, full equity acceleration, and 24 months of COBRA coverage.
- CIC Transaction: Triggers full equity acceleration for all awards, with performance-based awards vesting at the greater of actual performance or target levels.
- Management Retention Agreements (Ira Duarte, William Forbes, Mark Hensley): Amended and restated agreements were executed for the CFO, Chief Development Officer, and COO.
- Standard Involuntary Termination: Provides 12 months of base salary plus 100% of target/average bonus, 12 months of equity vesting acceleration, and 12 months of COBRA coverage.
- CIC Termination: Provides 24 months of base salary plus 200% of target/average bonus, full equity acceleration, and 24 months of COBRA coverage.
- CIC Transaction: Triggers full equity acceleration, with performance-based awards vesting at the greater of actual performance or target levels.
- Other Provisions: All agreements updated governing law and location to North Carolina, clarified definitions of "Change in Control," and included enhanced non-competition and non-solicitation covenants (24 months).
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or management commentary on business performance. The primary risk disclosed relates to the potential future cash outflows and equity dilution associated with the enhanced severance and acceleration provisions if a Change in Control or involuntary termination occurs.
Key Facts for Investor Verification
- Verify the total potential cash severance liability for the CEO and the three executives under both standard and Change in Control scenarios.
- Review the specific "Performance-Based Vesting Criteria" to understand the maximum potential equity dilution upon a Change in Control.
- Confirm the impact of the 24-month non-competition and non-solicitation covenants on the Company's ability to hire or be hired by competitors.
- Check the full text of Exhibits 10.1 through 10.4 for specific definitions of "Cause," "Good Reason," and "Involuntary Termination."